8 and routes of transmission,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 6, no. 8, pp. 941–948, 1993. [11] Z. J. Da Silva, I. Liveira, A. Andersen et al., “Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau: is HIV-2 disappearing?” AIDS, vol. 22, no. 10, pp. 1195–1202, 2008. [12] C. Van Tienen, M. F. Van Der Loeﬀ, S. M.A. Zaman et al., “Two distinct epidemics: the rise of HIV-1 and decline of HIV-2 infection between 1990 and 2007 in rural guinea- bissau,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 53, no. 5, pp. 640–647, 2010. [13] A. Wilkins, D. Ricard, J. Todd, H. Whittle, F. Dias, and A. P. Da Silva, “The epidemiology of HIV infection in a rural area of Guinea-Bissau,” AIDS, vol. 7, no. 8, pp. 1119–1122, 1993. [14] U. Dietrich, J. K. Maniar, and H. Rubsamen-Waigmann, “The epidemiology of HIV in India,” Trends in Microbiology, vol. 3, no. 1, pp. 17–21, 1995. [15] M. Smallman-Raynor and A. Cliﬀ, “The spread of human immunodeﬁciency virus type 2 into Europe: a geographical analysis,” International Journal of Epidemiology, vol. 20, no. 2, pp. 480–489, 1991. [16] M. O. Santos-Ferreira, T. Cohen, M. H. Lourenco, M. J. Matos Almeida, S. Chamaret, and L. Montagnier, “A study of seroprevalence of HIV-1 and HIV-2 in six provinces of People’s Republic of Angola: clues to the spread of HIV infection,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 3, no. 8, pp. 780–786, 1990. [17] J. Barreto, J. Liljestrand, C. Palha de Sousa et al., “HIV-1 and HIV-2 antibodies in pregnant women in the city of Maputo, Mozambique: a comparative study between 1982/1983 and 1990,” Scandinavian Journal of Infectious Diseases, vol. 25, no. 6, pp. 685–688, 1993. [18] E. Cortes, R. Detels, D. Aboulaﬁa et al., “HIV-1, HIV-2, and HTLV-I infection in high-risk groups in Brazil,” New England Journal of Medicine, vol. 320, no. 15, pp. 953–958, 1989. [19] J. Balzarini, “Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeﬁciency virus type 1,” Current Topics in Medicinal Chemistry, vol. 4, no. 9, pp. 921–944, 2004. [20] V. A. Johnson, F. Brun-Vezinet, B. Clotet et al., “Update of the drug resistance mutations in HIV-1: December 2009,” Topics in HIV Medicine, vol. 17, no. 5, pp. 138–145, 2009. [21] HIVdb: Genotypic Resistance Interpretation Algorithm, “Stanford University: HIV Drug Resistance Database,” http://sierra2.stanford.edu/sierra/servlet/JSierra. [22] L. Giuseppe, A. Soria, and A. Gori, “Pharmacotherapy of HIV: focus on etravirine,” Clinical Medicine, vol. 1, pp. 483– 494, 2009. [23] L. Siegel and R. M. Gulick, “New antiretroviral agents,” Current Infectious Disease Reports, vol. 9, no. 3, pp. 243–251, 2007. [24] P. Reid, H. MacInnes, M. E. Cong, W. Heneine, and J. G. Garcı´a-Lerma, “Natural resistance of human immunodeﬁ- ciency virus type 2 to zidovudine,” Virology, vol. 336, no. 2, pp. 251–264, 2005. [25] R. A. Smith, G. S. Gottlieb, D. J. Anderson, C. L. Pyrak, and B. D. Preston, “Human immunodeﬁciency virus types 1 and 2 exhibit comparable sensitivities to zidovudine and other nucleoside analog inhibitors in vitro,” Antimicrobial Agents and Chemotherapy, vol. 52, no. 1, pp. 329–332, 2008. [26] M. L. Ntemgwa, T. D. Toni, B. G. Brenner et al., “Nucleoside and nucleotide analogs select in culture for diﬀerent patterns of drug resistance in human immunodeﬁciency virus types 1 AIDS Research and Treatment and 2,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 2, pp. 708–715, 2009. [27] S. Jallow, S. Kaye, A. Alabi et al., “Virological and immuno- logical response to Combivir and emergence of drug resis- tance mutations in a cohort of HIV-2 patients in The Gambia,” AIDS, vol. 20, no. 10, pp. 1455–1458, 2006. [28] M. E. Van Der Ende, J. M. Prins, K. Brinkman et al., “Clinical, immunological and virological response to diﬀer- ent antiretroviral regimens in a cohort of HIV-2-infected patients,” AIDS, vol. 17, no. 3, pp. S55–S61, 2003. [29] C. A. Adje´-Toure´, R. Cheingsong, J. G. Garcı`a-Lerma et al., “Antiretroviral therapy in HIV-2-infected patients: changes in plasma viral load, CD4+ cell counts, and drug resistance proﬁles of patients treated in Abidjan, C oˆte d’Ivoire,” AIDS, vol. 17, supplement 3, pp. S49–S54, 2003. [30] R. A. Smith, D. J. Anderson, C. L. Pyrak, B. D. Preston, and G. S. Gottlieb, “Antiretroviral drug resistance in HIV-2: three amino acid changes are suﬃcient for classwide nucleoside analogue resistance,” Journal of Infectious Diseases, vol. 199, no. 9, pp. 1323–1326, 2009. [31] D. R. Kuritzkes, R. L. Bassett, J. D. Hazelwood et al., “Rate of thymidine analogue resistance mutation accumulation with zidovudine- or stavudine-based regimens,” Journal of Acquired Immune Deﬁciency Syndromes, vol. 36, no. 1, pp. 600–603, 2004. [32] B. Rode´s, A. Holguı´n, V. Soriano et al., “Emergence of drug resistance mutations in human immunodeﬁciency virus type 2-infected subjects undergoing antiretroviral therapy,” Journal of Clinical Microbiology, vol. 38, no. 4, pp. 1370–1374, 2000. [33] E. Brandin, L. Lindborg, K. Gyllensten et al., “pol gene sequence variation in Swedish HIV-2 patients failing antiretroviral therapy,” AIDS Research and Human Retro- viruses, vol. 19, no. 7, pp. 543–550, 2003. [34] S. Jallow, A. Alabi, R. Sarge-Njie et al., “Virological response to highly active antiretroviral therapy in patients infected with human immunodeﬁciency virus type 2 (HIV-2) and in patients dually infected with HIV-1 and HIV-2 in the gambia and emergence of drug-resistant variants,” Journal of Clinical Microbiology, vol. 47, no. 7, pp. 2200–2208, 2009. [35] G. S. Gottlieb, N. M. D. Badiane, S. E. Hawes et al., “Emergence of multiclass drug-resistance in HIV-2 in antiretroviral-treated individuals in Senegal: implications for HIV-2 treatment in resouce-limited West Africa,” Clinical Infectious Diseases, vol. 48, no. 4, pp. 476–483, 2009. [36] P. Colson, M. Henry, N. Tivoli et al., “Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in Southeastern France,” Journal of Medical Virology, vol. 75, no. 3, pp. 381–390, 2005. [37] J. N. Nkengasong, C. Adje-Toure, and P. J. Weidle, “HIV antiretroviral drug resistance in Africa,” AIDS Reviews, vol. 6, no. 1, pp. 4–12, 2004. [38] G. J. Moyle, “The K65R mutation: selection, frequency, and possible consequences,” AIDS Reader, vol. 14, no. 11, pp. 595–601, 2004. [39] F. Damond, S. Matheron, G. Peytavin et al., “Selection of K65R mutation in HIV-2-infected patients receiving tenofovir-containing regimen,” Antiviral Therapy, vol. 9, no. 4, pp. 635–636, 2004. [40] D. Descamps, F. Damond, S. Matheron et al., “High fre- quency of selection of K65R and Q151M mutations in HIV- 2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen,” Journal of Medical Virology, vol. 74, no. 2, pp. 197–201, 2004.